Table 1 Criteria of Selection for SLIT (Adapted From[4, 5])

• To be eligible for SLIT, patients should have the follow:

   A clinical history of allergy.

   Documented ALLERGEN-SPECIFIC IgE positive test.

   The allergen used for immunotherapy must be clinically relevant to their clinical history.

• Age does not seem to be a limitation.

• Monosensitized patients are ideal candidates for SLIT, and recently single-allergen SLIT has been demonstrated to be effective in polysensitized patients.

• Presently, use of SLIT in latex allergy, atopic dermatitis, food allergy, and hymenoptera venom allergy is under investigation: more demonstrations are needed to support clinical use.

• There is no indication whatsoever for treating non-IgE-mediated hypersensitivity (i.e., nickel sensitivity) with SLIT.

• SLIT may be considered as initial treatment; failure of pharmacological treatment is not an essential prerequisite for the use of SLIT.

• SLIT may be proposed as an early treatment in respiratory allergy therapeutic strategy.

• Special SLIT indications exist in the following patients:

   Patients uncontrolled with optimal pharmacotherapy (SCUAD).

   Patients in whom pharmacotherapy induces undesirable side effects.

   Patients refusing injections.

   Patients who do not want to be on constant or long-term pharmacotherapy.